Yicura BioMed Closes First Tranche of Series B Led by Gobi Partners

Gobi Partners led the first close of Yicura BioMed's Series B, funding its ICVAX HIV DNA vaccine toward Phase II after a favorable Phase I trial. Amounts undisclosed.